Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you recommend hypofractionated treatment for early stage, bilateral breast cancers?
Assume each primary meets ASTRO 2018 guidelines
Answer from: Radiation Oncologist at Community Practice
yes as i don't see any reason and have done multiple times
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Agreed, key is to ensure fields are set up to prevent any potential overlap
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Yes, check for overlap. Otherwise, there is no glaring contraindication.
Sign in or Register to read more
4383
4395
4397
Related Questions
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?
Would you recommend MRI post surgery and pre-irradiation for patients with extensive DCIS and close margins and how would it impact your management?
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?
What are your top takeaways in Radiation Oncology from SABCS 2024?
When treating APBI with the Florence regimen, are you using daily or every other day fractionation?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
Does radiation therapy (ex. to the breast) in patients with CDK4 mutations increase the risk of developing melanoma?
What hotspot and heterogeneity metrics do you utilize when delivering PMRT to a patient who has had breast reconstruction?